The triple x syndrome management market is projected to grow from USD 168.5 million in 2025 to USD 301.8 million by 2035, at a CAGR of 6.0%. Periodic Screening will dominate with a 48.6% market share, while hospitals will lead the end-users segment with a 55.2% share.